Effects of EGFR Inhibitors on Colon Cancer Cell Lines
Author Information
Author(s): Solmi Rossella, Lauriola Mattia, Francesconi Mirko, Martini Désirée, Voltattorni Manuela, Ceccarelli Claudio, Ugolini Giampaolo, Rosati Giancarlo, Zanotti Simone, Montroni Isacco, Mattei Gabriella, Taffurelli Mario, Santini Donatella, Pezzetti Furio, Ruggeri Alessandro, Castellani Gastone, Guidotti Lia, Coppola Domenico, Strippoli Pierluigi
Primary Institution: Università di Bologna
Hypothesis
How do cetuximab and gefitinib affect gene expression and cell morphology in human colon cancer cell lines?
Conclusion
Cetuximab and gefitinib have a weaker effect in the presence of EGF, leading to significant morphological changes and reduced cell viability in colon cancer cell lines.
Supporting Evidence
- Caco-2 cells showed a significant reduction in viability after treatment with EGF and EGFR inhibitors.
- HT-29 and Caco-2 cells displayed morphological changes indicative of apoptosis after treatment.
- Gene expression profiling revealed distinct patterns in response to cetuximab and gefitinib.
- Both drugs induced a reduction in microvilli, suggesting impaired absorption function.
- Combination treatments with EGF resulted in fewer affected genes compared to single treatments.
Takeaway
This study looked at how two cancer drugs, cetuximab and gefitinib, change the way colon cancer cells look and grow, especially when combined with a growth factor called EGF.
Methodology
Cell growth was measured using MTT assay, cell-cycle analysis was done by flow cytometry, and gene expression was analyzed using microarrays.
Limitations
The study may not fully represent in vivo conditions and the effects of autocrine loops were not considered.
Participant Demographics
HT-29 cells from a 44-year-old Caucasian female and Caco-2 cells from a 72-year-old Caucasian male.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website